The clinical impact of DNA methylation frequencies of JAK2 negative regulators in patients with essential Thrombocythemia

Leukemia Research

Volumn 36, Issue 5, 2012, Pages 588-590

  Födermayr, Mathilde ^a   Zach, Otto ^a   Huber, Maria ^a   Machherndl Spandl, Sigrid ^a   Wölfl, Soraya ^b   Bösmüller, Hans Christian ^c   Hasenschwandtner, Sonja ^d   Burgstaller, Sonja ^e   Krieger, Otto ^a   Lutz, Dieter ^a   Weltermann, Ansgar ^a   Hauser, Hanns ^a  

^a ELISABETHINEN HOSPITAL   (Austria)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

^c Pathology Krankenhaus der Barmherzigen Schwestern   (Austria)

^d Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

^e Klinikum Wels Grieskirchen GmbH   (Austria)

Author keywords

DNA methylation; Essential Thrombocythemia; PTPN6; SOCS1; SOCS3

Indexed keywords

GENOMIC DNA; JANUS KINASE 2;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; DISEASE ACTIVITY; DNA DETERMINATION; DNA METHYLATION; ENZYME ACTIVATION; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN TYROSINE PHOSPHATASE 6 GENE; REGULATOR GENE; SUPPRESSOR OF CYTOKINE SIGNALING 1 GENE; SUPPRESSOR OF CYTOKINE SIGNALING 3 GENE; THROMBOCYTHEMIA;

DNA METHYLATION; HUMANS; JANUS KINASE 2; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84858753411     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.01.008     Document Type: Article

References (16)

1. James C., Ugo V., Casadevall N., Constantinescu S.N., Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005, 11(12):546-554.
2. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
3. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
4. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., McCubrey J.A. JAK/STAT, Raf/MEK/ERK PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18:189-218.
5. Valentino L., Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 2006, 71:713-721.
6. Scott L.M., Campbell P.J., Baxter E.J., et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005, 106(8):2920-2921.
7. Capello D., Deambrogi C., Rossi D., et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 2008, 141:504-511.
8. Scott L.M., Beer P.A., Bench A.J., Erber W.N., Green A.R. Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol 2007, 139(3):511-512.
9. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108(10):3472-3476.
10. Fernández-Mercado M., Cebrián V., Euba B., et al. Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms. Leuk Res 2008, 10:1638-1640.
11. Kröger N., Badbaran A., Holler E., et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2006, 109(3):1316-1321.
12. Alizadeh M., Bernard M., Danic B., et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002, 99(12):4618-4625.
13. Teofili L., Martini M., Cenci T., et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer 2008, 123:1586-1592.
14. Fourouclas N., Li J., Gilby D.C., et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 2008, 93(11):1635-1644.
15. Jost E., do Oó N., Dahl E., et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia 2007, 21(3):505-510.
16. Barrio S., Gallardo M., Albizua E., et al. Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation. J Clin Pathol 2011, 64:1010-1013.